HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.

AbstractBACKGROUND:
The frequency of aromatase inhibitor (AI)-associated arthralgia and/or bone pain in clinical practice is not known.
PATIENTS AND METHODS:
Fifty-six consecutive patients with breast cancer not on clinical trials who were receiving AIs in a clinical practice were interviewed regarding occurrence of worsening or new arthralgia and/or bone pain after starting AI therapy. The occurrence, character, severity, and resolution of pain were evaluated.
RESULTS:
Arthralgia and/or bone pain was reported in 61% of patients. It was severe in 30%, continuous in 41%, central in 50%, peripheral in 79%, and resulted in discontinuation of the drug in 20% of patients. Effective therapies in controlling pain were acetaminophen, 29%; nonsteroidal anti-inflammatory drugs, 50%; opiates, 18%, and glucosamine in 15% of patients. Despite this, 20% of patients discontinued AI therapy because of pain.
CONCLUSION:
Aromatase inhibitor-associated pain is more frequent in patients not in clinical trials than previously appreciated in clinical trials. Improved patient education is needed, and prompt therapeutic management of pain is required to ensure continued drug treatment and improved quality of life.
AuthorsCary A Presant, Linda Bosserman, Traci Young, Mayank Vakil, Richard Horns, Gargi Upadhyaya, Behnam Ebrahimi, Christina Yeon, Frank Howard
JournalClinical breast cancer (Clin Breast Cancer) Vol. 7 Issue 10 Pg. 775-8 (Oct 2007) ISSN: 1526-8209 [Print] United States
PMID18021478 (Publication Type: Journal Article)
Chemical References
  • Aromatase Inhibitors
Topics
  • Aromatase Inhibitors (adverse effects, therapeutic use)
  • Arthralgia (chemically induced, epidemiology)
  • Bone and Bones (pathology)
  • Breast Neoplasms (drug therapy)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Pain (chemically induced, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: